Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CRHBP | P24387 | 1/20 | 0.36 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17595432 | 1.00 | HTT (0.43) | HTTSMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL25331076 | 0.89 | RAB9A (0.47) | HTTSMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL17593772 | 0.88 | HTT (0.43) | HTTSMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL14862556 | 0.88 | HTT (0.43) | HTTSMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL19302582 | 0.83 | MEN1 (0.55) | KMT2AMEN1 | |
| SCHEMBL17592844 | 0.80 | MEN1 (0.44) | HTTSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL17592842 | 0.80 | MEN1 (0.44) | HTTSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL34473463 | 0.79 | HTT (0.43) | HTTSMN1; SMN2NPC1RAB9AGAA | |
| SCHEMBL19253860 | 0.78 | MEN1 (0.39) | HTTSMN1; SMN2NPC1RAB9AKMT2A | |
| SCHEMBL19253859 | 0.78 | MEN1 (0.39) | HTTSMN1; SMN2NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240156969-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEAGEN INC (US) | 2024-05-16 | — | — | US | disclosed |
| EP-3900742-B1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | SEAGEN INC (US) | 2024-05-15 | — | — | EP | disclosed |
| US-11945807-B2 | Splicing modulator antibody-drug conjugates and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2024-04-02 | — | — | US | disclosed |
| US-11793880-B2 | Conjugates of quaternized tubulysin compounds | SEAGEN INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20220226482-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEAGEN INC (US) | 2022-07-21 | — | — | US | disclosed |
| US-11352348-B2 | Splicing modulator antibody-drug conjugates and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-07 | — | — | US | disclosed |
| EP-3383420-B1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEAGEN INC (US) | 2022-03-23 | — | — | EP | disclosed |
| US-11229708-B2 | Conjugates of quaternized tubulysin compounds | SEAGEN INC. (US) | 2022-01-25 | — | — | US | disclosed |
| EP-3900742-A1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | Seagen Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| US-20210299269-A1 | SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-09-30 | — | — | US | disclosed |
| EP-3191502-B1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | SEAGEN INC (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-3801632-A1 | SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Eisai R&D Management Co., Ltd. (JP) | 2021-04-14 | — | — | EP | disclosed |
| US-20210101888-A1 | SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-04-08 | — | — | US | disclosed |
| WO-2019232449-A9 | SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-09-24 | — | — | WO | disclosed |
| US-20190015517-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | SEATTLE GENETICS, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20170247412-A1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | SEATTLE GENETICS, INC. (US) | 2017-08-31 | — | — | US | disclosed |
| EP-3191502-A1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | Seattle Genetics, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016040684-A1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | SEATTLE GENETICS, INC (US) | 2016-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11945807-B2 | Splicing modulator antibody-drug conjugates and methods of use | RBM17, RBM22, SF3B1 | HTT 4107/4885SMN1; SMN2 305/4885NPC1 4654/4885 |
| US-20170247412-A1 | TARGETED DELIVERY OF TERTIARY AMINE-CONTAINING DRUG SUBSTANCES | CD47, CD44, MSR1 | HTT 1048/4885SMN1; SMN2 875/4885NPC1 741/4885 |
| US-11352348-B2 | Splicing modulator antibody-drug conjugates and methods of use | RBM17, RBM22, SF3B1 | HTT 4107/4885SMN1; SMN2 305/4885NPC1 4654/4885 |
| US-20220226482-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | LCK, UACA, TEKT1 | HTT 851/4885SMN1; SMN2 3157/4885NPC1 3444/4885 |
| US-20210101888-A1 | SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | RBM17, RBM22, SF3B1 | HTT 4107/4885SMN1; SMN2 305/4885NPC1 4654/4885 |
| US-20210299269-A1 | SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | RBM17, RBM22, SF3B1 | HTT 4107/4885SMN1; SMN2 305/4885NPC1 4654/4885 |
| US-11229708-B2 | Conjugates of quaternized tubulysin compounds | LCK, UACA, TEKT1 | HTT 851/4885SMN1; SMN2 3157/4885NPC1 3444/4885 |
| US-20190015517-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | LCK, UACA, TEKT1 | HTT 851/4885SMN1; SMN2 3157/4885NPC1 3444/4885 |
| US-20240156969-A1 | CONJUGATES OF QUATERNIZED TUBULYSIN COMPOUNDS | LCK, UACA, TEKT1 | HTT 851/4885SMN1; SMN2 3157/4885NPC1 3444/4885 |
| US-11793880-B2 | Conjugates of quaternized tubulysin compounds | LCK, UACA, TEKT1 | HTT 851/4885SMN1; SMN2 3157/4885NPC1 3444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.